China Pharma Holdings, Inc.

158 articles about China Pharma Holdings, Inc.

• China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split

  2/24/2023

  China Pharma Holdings Inc. reported that it expects to implement a 1-for-10 reverse stock split on its common stock effective Monday, March 6, 2023, with trading to begin on a split-adjusted basis at the market open on that day.

• China Pharma Holdings, Inc. Announced the Launch of N95 Medical Protective Mask

  12/28/2022

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced the launch of N95 medical protective mask.

• China Pharma Holdings, Inc. Announced that several products are included in the Catalogue of Medicines for People Infected with COVID-19

  12/15/2022

  China Pharma Holdings, Inc. announced that its drugs were listed in The Catalogue of Medicines for People Infected with COVID-19 published by People's Daily on December 12, 2022.

• China Pharma Announced the Submission of a Plan of Compliance to NYSE American

  7/18/2022

  China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), a specialty pharmaceutical company, today announced that on July 15, 2022 , the Company submitted a plan of compliance to NYSE American LLC ("NYSE American" or the "Exchange") to address the deficiency in the Company's stockholders' equity as pointed out in the letter from the Exchange dated June 15, 2022 (the "Letter").

• China Pharma Announces Receipt of Noncompliance Notice from NYSE American

  6/22/2022

  China Pharma Holdings, Inc., a specialty pharmaceutical company, announced that on June 15, 2022, the Company received a letter from NYSE American LLC stating that the Company was not in compliance with the continued listing standards as set forth in Section 1003 of the NYSE American Company Guide.

• China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results

  3/31/2022

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the fiscal year ended December 31, 2021.

• China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results

  11/12/2021

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced the financial results for the quarter ended September 30, 2021.

• China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results

  8/13/2021

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced the financial results for the quarter ended June 30, 2021.

• China Pharma's Candesartan Hypertension Product Passes Bioequivalence Tests and the Company Plans to Apply for NMPA Approval

  8/5/2021

  China Pharma Holdings, Inc., a specialty pharmaceutical company, announced that its Candesartan hypertension product passed key bioequivalence tests.

• China Pharma to Launch Highly Purified NMN+PQQ Product

  6/9/2021

  China Pharma Holdings, Inc., a specialty pharmaceutical company, announced plans to launch a highly purified NMN+PQQ product following the recent successful completion of a pilot scale test.

• China Pharma Holdings, Inc. Reports 33% YoY Increase in First Quarter 2021 Revenue

  5/14/2021

  China Pharma Holdings, Inc.China Pharma Holdings, Inc., a specialty pharmaceutical company, announced financial results for the quarter ended March 31, 2021.

• China Pharma Expects Considerable Increase in Growth Opportunities Related to Hainan Free Trade Port

  4/19/2021

  China Pharma Holdings, Inc., a specialty pharmaceutical company, commented on the policy statements in "Several Special Measures to Support the Construction of Hainan Free Trade Port to Relax Market Access" released by the National Development and Reform Commission and the Ministry of Commerce in April.

• China Pharma Holdings, Inc. Reports Fiscal Year 2020 Financial Results

  3/26/2021

  China Pharma Holdings, Inc. (NYSE American: CPHI)  ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced financial results for the fiscal year ended December 31 , 20 20 .

• China Pharma Holdings, Inc. Reports Third Quarter 2020 Financial Results

  11/13/2020

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the quarter ended September 30, 2020.

• China Pharma Holdings, Inc. Reports Second Quarter 2020 Financial Results

  8/14/2020

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the quarter ended June 30, 2020.

• China Pharma Holdings, Inc. Reports First Quarter 2020 Financial Results

  5/15/2020

  China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China , today announced financial results for the quarter ended March 31, 2020 . First Quarter Highlights Revenue decreased

• Updates - China Pharma Holdings, Inc. Reports Fiscal Year 2019 Financial Results

  4/14/2020

  China Pharma Holdings, Inc. announced that it is re-issuing its previous release that was made on March 31, 2020 to incorporate certain disclosures that are required under the NYSE American Company Guide Sections 401 and 610.

• China Pharma Holdings, Inc. Reports Fiscal Year 2019 Financial Results

  3/31/2020

  China Pharma Holdings, Inc., an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced financial results for the fiscal year ended December 31, 2019.

• Research Studies Progressing Towards New FDA Approved Treatments for Glioblastoma

  3/3/2020

  Although there is presently no cure for glioblastoma, researchers are continually inching closer to new and effective treatment options.

• China Pharma Holdings, Inc. Reports Third Quarter 2019 Financial Results

  11/15/2019

  China Pharma Holdings, Inc.,  (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the quarter ended September 30, 2019.